Fig. 1
![Fig. 1](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40880-018-0312-1/MediaObjects/40880_2018_312_Fig1_HTML.jpg)
Lesions in case 1. Gd-EOB-DTPA-enhanced MR images showing, at baseline acquisition, hepatobiliary phase 4 millimetric lesions: a 10 mm hepatocellular carcinoma (HCC) nodule in segment II (a), a 14 mm HCC nodule in segment III (b), and a millimetric lesion at segments V and I. Gd-EOB-DTPA-enhanced MR follow-up after 89 months since starting systemic treatment with metronomic capecitabine shows a stable complete response, with the absence of both HCC nodules (c, d)